Tx Medic Ab

Uddeholms Aktiebolag

Prophy Med Ab

Tigran Technologies Ab

Ab Idea

Tikomed Ab

Lanka Limited

Ticapex Ab

Lars M Bruce

Ingrid E Bruce

Adam Bruce

Staale Lyngstadaas

Anders Waas

Ulf Brasen

Bo Nilsson

Olle Korsgren

Billy Nilson

Staale Petter Lyngstadaas

A method for dissolving scars comprises administering dextran sulfate, or a pharmaceutically acceptable salt thereof, to a subject suffering from fibrosis or a fibrotic disease, disorder or condition to dissolve an established scar in the subject.

Method for dissolving scars with dextran sulfate

Dextran sulfate, or a pharmaceutically acceptable derivative thereof, is used to induce differentiation of glial cells and neurons. The cell differentiation induction of dextran sulfate has positive effects in subjects suffering from neurological diseases, including neurodegenerative diseases, demyelinating diseases, neuro ischemic diseases and neuromuscular diseases.

Use of dextran sulfate

The present embodiments generally relate to dextran sulfate, or a pharmaceutically acceptable salt thereof, for use in treating, inhibiting or preventing glaucoma in a subject. Dextran sulfate of the embodiments achieves a reduction and normalization of intraocular pressure, a neuroprotective effect in terms of preserving retinal ganglion cells and retinal nerve fiber layer and dissolves established trabecular meshwork scar elements.

Treatment of glaucoma

The present embodiments relate to the use of dextran sulfate having an average molecular weight below 10 000 Da for inducing angiogenesis in a subject and for increasing blood flow in a subject suffering from ischemia.

Methods of treating, inhibiting and/or preventing instant blood-mediated inflammatory reaction (IBMIR) comprise administering, to a subject, a dextran sulfate characterized by a number average molecular weight (M) as measured by nuclear magnetic resonance (NMR) spectroscopy within an interval of 1850 and 3500 Da; an average sulfate number per glucose unit within an interval of 2.5 and 3.0; and an average sulfation of C2 position in the glucose units of said dextran sulfate of at least 90%, or a salt of such a dextran sulfate.

Dextran sulfate

Use of dextran sulfate having an average molecular weight below 10000 DA for inducing angiogenesis in a subject

The present embodiments relate to the use of dextran sulfate formulated for systemic administration for treatment, inhibition or prevention of cardiac fibrosis in a subject.

A dextran sulfate, or a salt thereof, has a number average molecular weight (Mn) as measured by NMR spectroscopy within an interval of 1850 and 3500 Da. The dextran sulfate, or the salt thereof, also has an average sulfate number per glucose unit within an interval of 2.5 and 3.0. Furthermore, an average sulfation of C2 position in the glucose units of the dextran sulfate, or the salt thereof, is at least 90%. The dextran sulfate has improved biological effects and/or reduced toxicity as compared to similar dextran sulfate molecules available on the market.

Surface-binding peptides have the capability of binding to surfaces of biocompatible materials and can thereby be used to immobilize various heterologous molecules of interest onto the surface. This means that surfaces of, for instance, implants and implantable medical devices can be tailored to present various characteristics by immobilizing selected heterologous molecules of interest on the surfaces of the implants and implantable medical devices. The surface-binding peptides consist of 5-17 consecutive amino acids of an extended beta-hairpin motif EIIATMKKKGEKRCLNP (SEQ ID NO: 57) in Interferon gamma-induced protein 10 (IP-10).

Surface-binding peptide

A body fluid purifying arrangement comprises a purifying chamber having a fluid input and a fluid output, a first filter arranged in connection the fluid input, and a second filter arranged in connection with the fluid output. In another embodiment, a body fluid purifying arrangement in the form of a syringe comprises a purifying chamber having a common fluid input and fluid output, and a filter arranged in connection with the common fluid input and output. Granules or particles made of a metal or an oxide of a metal are retained within the purifying chamber by the respective filter(s) to purify a body fluid passing through the purifying chamber from 10 kDa interferon-&#x3b3; inducible protein, IP-10, wherein said metal is a metal of group 4 or 5 of the periodic table of the elements and selected from the group consisting of titanium, zirconium, hafnium, niobium and tantalum.

Selective chemokine modulation

A method of treating or preventing a disease characterized by adverse expression and/or release of 10 kDa interferon-&#x3b3; inducible protein, IP-10, comprises administering granules or particles made of a metal or an oxide of a metal to a subject suffering from the disease. A method of reducing IP-10 in a subject suffering from a disease characterized by adverse expression and/or release of IP-10 comprises administering granules or particles made of a metal or an oxide of a metal to the subject. The metal is a metal of group 4 or 5 of the periodic table of the elements and selected from the group consisting of titanium, zirconium, hafnium, niobium and tantalum.

The present invention teaches the use of a metal or an oxide of a metal having a capability of reducing the amount of the chemokine IP-IO in a sample and/or reducing the production of IP-IO in cells. The metal is a metal of group 4 or 5 in the periodic table of the elements and preferably titanium. These metals and metal oxides can selectively bind IP-IO to its surface to thereby scavenge IP-IO from the surrounding medium. In addition, a metal-cell contact induces a reduction in the production of IP-IO from IP-IO producing cells. The metals and metal oxides of the present invention can therefore be used for treating and/or preventing medical conditions characterized by adverse IP-IO expression, such as inflammatory reactions.

A bioartificial implant comprises a semipermeable barrier designed from one side to allow diffusion or prevent diffusion of predetermined substances/materials/molecules/cells/cell lines produced in the human body to the other opposite side of the barrier, and from said other opposite side to allow diffusion or prevent diffusion of predetermined substances which are the same as or different from the first mentioned substances/materials/molecules/cells/cell lines. The semipermeable barrier has a surface coating at least on said one side a bioactive metal, such as titanium, which surface coating is permeable to allow said diffusions. In a method for reducing the risk of formation/growth of connective tissue in connection with an implant which comprises a semipermeable barrier, the barrier is provided at least on one side with a permeable coating of bioactive metal. An example of the use of the implant is bioartificial pancreas.

Bioartificial implant and its use and method of reducing the risk for formation of connective tissue after implantation

The present invention relates to an irregularly shaped grain for providing ingrowth and growth of connective tissue as well as growth of other cell types leading to cluster of cells, tissues and parts of organs. Said grain includes multiple pores that are continuous through said grain, and openings of said multiple pores and ducts or passages interconnecting at least a portion of said multiple pores have a width of greater than about 10 &#x3bc;m. Said grain is preferably a metal or metal alloy. The invention also relates to different applications of the grains.

Grain for providing cell growth

A body, such as a grain, for providing ingrowth and growth of bone tissue and/or connective tissue. The body consists of a plastic or non-essentially elastic biocompatible material, preferably metal or metal alloy. It is also porous, having the following porosity characteristics: (a) the porosity is continuous and (b) the opening of cavities/indentations/pockets and the ducts connecting them has the width of &#x3e;about 50 &#x3bc;m for bone tissue and &#x3e;about 10 &#x3bc;m for connective tissue. In a method of making such a body, the body has been produced by blowing gas into a melt of metal. An advantageous use of bodies according to the invention is enclosing thereof in a casing, formed with openings, for making an implant, such as a spinal implant.

Growing community of inventors

Viken, Sweden

Lars M Bruce